Abstract
Executive Summary
The elaborate advances towards the blueprinting of the altered molecular
networks that lie behind cancer development have paved the way for targeted
therapy in cancer. There are currently more than 400 antibody based drugs in
development for the treatment of cancer. What and where they are targeting has
to date only been a fragmented knowledge. First in place, BioSeeker has
surveyed these antibodies and identified 132 antibody drug targets, belonging
to 220 antibody drugs. In all they range from preclinical development to
established therapy leaders in the market place. Drug targets and their
associated antibodies have been analyzed by BioSeeker according to:
- 34 Different molecular functions of target
- 13 Major signaling pathways
- Cancer stem cells
- Conjugated antibodies
- Therapeutic effects: Anti-angiogenesis, Apoptosis and Protein Kinase
Inhibition
- 31 Targeted cancer indications
- Availability of expression profiles of targets in human tissues, cancer
tissues, established cell lines and primary cell cultures
- Antibody therapeutic companies
Single target analysis of the 132 antibody targets is performed, including
targeted cancer indications, antibody drugs involved and their developmental
stages. In total more than 420 clinical trials are included in this analysis,
covering more than 30 different cancer indications plus diagnosis and
supportive care.
This report serves as a serious reference for professionals interested in the
development of oncology drug targets and selection/validation of targeting
strategies.
View Cart
